Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Sarah J Welsh"'
Autor:
Thomas J Mitchell, Hao Li, Grant D Stewart, Anne Y Warren, James N Armitage, Ferdia A Gallagher, Mary A McLean, Andrew N Priest, Andrew B Gill, Iosif Mendichovszky, João Duarte, Ines Horvat-Menih, Maria Jesus Zamora-Morales, Marta Wylot, Joshua Kaggie, Alixander S Khan, Matthew J Locke, Sarah J Welsh, James O Jones
Publikováno v:
BMJ Open, Vol 14, Iss 10 (2024)
Introduction Localised renal masses are an increasing burden on healthcare due to the rising number of cases. However, conventional imaging cannot reliably distinguish between benign and malignant renal masses, and renal mass biopsies are unable to c
Externí odkaz:
https://doaj.org/article/90752ec8113d439d8fdb872d49956c6c
Autor:
Stephan Ursprung, Andrew N Priest, Fulvio Zaccagna, Wendi Qian, Andrea Machin, Grant D Stewart, Anne Y Warren, Timothy Eisen, Sarah J Welsh, Ferdia A Gallagher, Tristan Barrett
Publikováno v:
PLoS ONE, Vol 16, Iss 10, p e0258988 (2021)
PurposeTo detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI.MethodParticipants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun clinical trial (EudraCtNo:
Externí odkaz:
https://doaj.org/article/20515c19e0624629b73c35ebcbaccf68
Autor:
Christopher G. Smith, Tina Moser, Florent Mouliere, Johanna Field-Rayner, Matthew Eldridge, Anja L. Riediger, Dineika Chandrananda, Katrin Heider, Jonathan C. M. Wan, Anne Y. Warren, James Morris, Irena Hudecova, Wendy N. Cooper, Thomas J. Mitchell, Davina Gale, Andrea Ruiz-Valdepenas, Tobias Klatte, Stephan Ursprung, Evis Sala, Antony C. P. Riddick, Tevita F. Aho, James N. Armitage, Samantha Perakis, Martin Pichler, Maximilian Seles, Gabriel Wcislo, Sarah J. Welsh, Athena Matakidou, Tim Eisen, Charles E. Massie, Nitzan Rosenfeld, Ellen Heitzer, Grant D. Stewart
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-17 (2020)
Abstract Background Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a combination of untargeted and targeted sequencing methods, applied
Externí odkaz:
https://doaj.org/article/2a2d59f651d64baaa2bf45b983922529
Publikováno v:
BJU International. 131:566-568
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14479df2c83bf9c8e4bef018b5a0d691
https://doi.org/10.1111/bju.15966
https://doi.org/10.1111/bju.15966
Autor:
Su Yin Lim, Jenny H. Lee, Sarah J. Welsh, Seong Beom Ahn, Edmond Breen, Alamgir Khan, Matteo S. Carlino, Alexander M. Menzies, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Biomarker Research, Vol 5, Iss 1, Pp 1-12 (2017)
Abstract Background Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patien
Externí odkaz:
https://doaj.org/article/3cb14fc94d8f4075b26767e4e07c1b24
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fba7a4c3002c9cc8f82b28dcf07d21
https://doi.org/10.1158/1078-0432.22487043
https://doi.org/10.1158/1078-0432.22487043
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Purpose:MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a90975dd8fcf92fc4c41ce20296e40
https://doi.org/10.1158/1078-0432.c.6532443.v1
https://doi.org/10.1158/1078-0432.c.6532443.v1
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05f7f333933fe113b04c91d3acc099d4
https://doi.org/10.1158/1078-0432.22487034.v1
https://doi.org/10.1158/1078-0432.22487034.v1
Autor:
Martin H. Voss, Arun A. Azad, Aaron R. Hansen, Jhanelle E. Gray, Sarah J. Welsh, Xuyang Song, Michael Kuziora, Lina Meinecke, Jorge Blando, Ikbel Achour, Yi Wang, Farzana L. Walcott, Sjoukje F. Oosting
Publikováno v:
Clinical Cancer Research. 28:3032-3041
Purpose: MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55420514f94145973854f58d3787e609
https://doi.org/10.1158/1078-0432.ccr-21-4115
https://doi.org/10.1158/1078-0432.ccr-21-4115
Autor:
Ruoyan Li, John R. Ferdinand, Kevin W. Loudon, Georgina S. Bowyer, Sean Laidlaw, Francesc Muyas, Lira Mamanova, Joana B. Neves, Liam Bolt, Eirini S. Fasouli, Andrew R.J. Lawson, Matthew D. Young, Yvette Hooks, Thomas R.W. Oliver, Timothy M. Butler, James N. Armitage, Tev Aho, Antony C.P. Riddick, Vincent Gnanapragasam, Sarah J. Welsh, Kerstin B. Meyer, Anne Y. Warren, Maxine G.B. Tran, Grant D. Stewart, Isidro Cortés-Ciriano, Sam Behjati, Menna R. Clatworthy, Peter J. Campbell, Sarah A. Teichmann, Thomas J. Mitchell
Tumor behavior is intricately dependent on the oncogenic properties of cancer cells and their multi-cellular interactions. To understand these dependencies within the wider microenvironment, we studied over 270,000 single-cell transcriptomes and 100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::158b71c82fe7745e4ec25d34b1051334